La sindrome del lobo medio La sindrome del lobo medio fernando maria de benedictis fernando maria de benedictis Azienda Ospedaliero-Universitaria “Ospedali Riuniti” - Ancona Ospedale Pediatrico di Alta Specializzazione “G. Salesi” Dipartimento di Pediatria
26
Embed
La sindrome del lobo medio fernando maria de benedictis Azienda Ospedaliero-Universitaria “Ospedali Riuniti” - Ancona Ospedale Pediatrico di Alta Specializzazione.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
La sindrome del lobo medioLa sindrome del lobo medio
fernando maria de benedictisfernando maria de benedictis
Azienda Ospedaliero-Universitaria “Ospedali Riuniti” - AnconaOspedale Pediatrico di Alta Specializzazione “G. Salesi”
Dipartimento di Pediatria
“I have not given the middle lobe syndrome agreat deal of respect ….”
EditorialRespecting the Middle Lobe Syndrome
Rubin, Pediatr Pulmonol 2006;41:803
The middle lobe syndrome in children is characterized by
a spectrum of clinical and radiographic presentations,
from persistent to recurrent atelectasis to pneumonitis
and bronchiectasis of the right middle lobe and/or lingula
Middle Lobe Syndrome:what’s in the name ?
Middle Lobe Syndrome: a 70-year-old story
Brock, 1937 First description of MLS (secondary to TB adenopathy)
GrahamGraham, 1948 First non-TB cases
Paulson, 1949 Description of anatomy of RML bronchus Harper, 1950 Description of involvement of lingula
Bradam, 1966 Role of chronic infection of RML
Culiner, 1966 Role of poor collateral ventilation of RML
In half of the population, MLS were unnoticed, although symptoms
persisted for many months
55 children with MLS, mean age 5.5 yrs - Asthma, CF, PCD, Immunodeficit 55 children with MLS, mean age 5.5 yrs - Asthma, CF, PCD, Immunodeficit excludedexcluded
Mean duration of symptoms 14.5 months – Mean follow-up for 24 monthsMean duration of symptoms 14.5 months – Mean follow-up for 24 months
0
20
40
60
80
100
Boys Atopy Frequentdyspnea
Sputumproduction
Duration ofsymptoms
MLS Control
Middle lobe syndrome in children with asthmaMiddle lobe syndrome in children with asthma
Extension and characteristics of parenchymal damage
Bronchiectasis
Patency of RML bronchus
Mediastinal lymph nodes
Middle lobe syndromeDiagnostic tools (2)
%
Total patients No bronchiectasis Bronchiectasis
40/75 (73%)
55 pts
15/55 (27%)
55 children with MLS - Duration of symptoms before presentation from 3 to 48 months 55 children with MLS - Duration of symptoms before presentation from 3 to 48 months HRCT scanHRCT scan performed after an aggressive medical treatment performed after an aggressive medical treatment
There was a positive correlation between the
duration of symptoms and the development of bronchiectasis
The role of timely intervention in middle lobe syndrome The role of timely intervention in middle lobe syndrome in childrenin children
55 children with MLS, median age 5,5 yrs55 children with MLS, median age 5,5 yrsAggressive timely interventionAggressive timely intervention – Follow-up for 24 months – Follow-up for 24 months
%
No bronchiectasis (n. 40) Bronchiectasis (n. 15)
Response to management
CureCureBetterBetterNo changeNo change
There was a clear association between the presence of
bronchiectasis and an unfavorable clinical and radiographic outcome
The role of timely intervention in middle lobe syndrome The role of timely intervention in middle lobe syndrome in childrenin children
“FOB has been recognized as a useful and safe tool in the investigation of infants and
children with airway diseases, including persistent atelectasis”
Midulla, ERS Task Force ERJ 2003;22:698
Fibroptic bronchoscopy
Patency of the RML bronchus
BAL: cells profile and microbiology
Biopsy
The role of timely intervention in middle lobe syndrome The role of timely intervention in middle lobe syndrome in childrenin children
55 children with MLS, median age 5,5 yrs55 children with MLS, median age 5,5 yrsBronchoscopyBronchoscopy and BAL after radiographyc diagnosis and BAL after radiographyc diagnosis
BAL fluid cellular components Microbiology
36
9 9
3 3 3 3
%
H Influenzae
S Pneumoniae
S aureus
M catarrhalis
P aeruginosa
Mucobacteria
Fungi
5851
1012
3
%
Eosinophil
Neutrophil
Lynphocyte
Macrophages
Normal
MLS is strengthly associated with asthma, and chronic inflammation of the lung is
present in more than half of population
Over half of the patients have an underlying bacterial
infection, although none had clinically diagnosed
pneumonia
Priftis, Chest 2005;128:2504
Conservative treatment
Antibiotics
Chest physiotherapy and postural drainage
Inhaled bronchodilators
Inhaled corticosteroids
Systemic corticosteroids
Mucolytics
Middle lobe syndromeManagement
1st step: Bronchoscopy
Removal of foreign bodies, retained secretions, tumor
2nd step: Surgical resection
• recurrent atelectasis or failure of RML to re-expand after conservative therapy and bronchoscopy
• presence of severe bronchiectasis
• extensive infection / destruction of a lobe or segment refractory to medical therapy